Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 4.

Article

Moller, DS, Nielsen, TB, Brink, C et al. (14 more authors) (2017) Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study. Radiotherapy and Oncology, 124 (2). pp. 311-317. ISSN 0167-8140

Proceedings Paper

Persson, G, Schytte, T, Appelt, AL orcid.org/0000-0003-2792-9218 et al. (16 more authors) (2019) Locally advanced NSCLC: performance status based eligibility for adjuvant check point inhibitor. In: Radiotherapy and Oncology. ESTRO 38, 26-30 Apr 2019, Milan, Italy. Elsevier , S739-S740.

Nielsen, TB, Brink, C, Moeller, DS et al. (10 more authors) (2016) EP-1932: Quality assurance in implementing a national dose escalation trial in NSCLC – report from NARLAL2. In: Radiotherapy and Oncology. ESTRO 35, 29 Apr - 03 May 2016, Turin, Italy. Elsevier , S916-S917.

Moeller, DS, Hoffmann, L, Lutz, CM et al. (10 more authors) (2016) OC-0544: Heterogeneous FDG-guided dose escalation of locally advanced NSCLC, the NARLAL2 phase III trial. In: Radiotherapy and Oncology. ESTRO 35, 29 Apr - 03 May 2019, Turin, Italy. Elsevier , S259-S259.

This list was generated on Mon Nov 25 01:36:22 2019 GMT.